Form 4: Guardian Pharmacy Services Director Sells Over 1.2 Million Shares in Underwritten Offering

John Ackerman, a Director and 10% owner of Guardian Pharmacy Services, Inc., sold a total of 1,284,579 shares of Class A Common Stock for $20.16 per share through an underwriting agreement.

Summary

• John Ackerman, a Director and 10% owner of Guardian Pharmacy Services, Inc. (GRDN), reported sales of Class A Common Stock.
• On May 27, 2025, 813,318 shares were sold directly at $20.16 per share.
• Also on May 27, 2025, 270,958 shares were sold directly at $20.16 per share.
• On May 28, 2025, 150,998 shares were sold directly at $20.16 per share.
• Also on May 28, 2025, 50,305 shares were sold directly at $20.16 per share.
• The total number of shares sold across these transactions is 1,284,579.
• These sales were conducted pursuant to an Underwriting Agreement dated May 22, 2025, involving the Issuer, selling stockholders, and Raymond James & Associates, Inc. as representative of the underwriters.
• Following these transactions, indirect beneficial ownership includes 600,622 shares and 449,624 shares by Pharmacy Investors, LLC, and 200,099 shares and 149,794 shares by Cardinal Equity Fund, L.P.

Sentiment

Score: 5

Explanation: The sale by a director and 10% owner is a significant divestment, which can be viewed negatively. However, the fact that it's part of an underwriting agreement suggests a structured, potentially pre-announced event (like a secondary offering post-IPO), which mitigates the negative perception compared to an unannounced open market sale. It's neutral to slightly negative depending on the context of the offering.

Positives

• The sale was part of a structured underwriting agreement, suggesting an organized capital markets transaction rather than an ad-hoc open market sale by an insider, which can provide liquidity for existing shareholders.

Negatives

• A significant sale of shares by a director and 10% owner, totaling approximately $25.9 million, could be perceived negatively by the market, potentially indicating a desire to diversify holdings or a lack of confidence, depending on the broader context of the offering.

Future Outlook

NA

Industry Context

This transaction is an insider sale, likely part of a secondary offering in the healthcare services or pharmacy sector. Such offerings are typically used to provide liquidity for early investors or founders, or to raise capital for corporate purposes. The market's interpretation of this event will depend on the company's growth prospects and the specific reasons communicated for the offering.

Related Party Transactions

• The sales involve entities (Pharmacy Investors, LLC and Cardinal Equity Fund, L.P.) with indirect beneficial ownership, suggesting potential related party involvement in the transaction, although the filing itself is about the direct sales by John Ackerman.

Stakeholder Impact

• Shareholders: The sale of a significant number of shares by a director and 10% owner could lead to concerns about insider confidence, potentially impacting stock price. However, if part of a secondary offering, it could increase liquidity.
• Investors: Provides transparency on insider holdings and transactions, which is crucial for investment decisions.

Key Dates

Recommendation

Keywords

Guardian Pharmacy Services, GRDN, SEC Form 4, Insider Trading, Stock Sale, Director Sale, 10% Owner, Underwriting Agreement, Equity Offering, John Ackerman, Pharmacy Investors LLC, Cardinal Equity Fund L.P.